ISRCTN11824145已完成不适用
A Randomised Trial of Two Chemotherapy Regimens in the Treatment of Operable Osteosarcoma (Doxorubicin-Cisplatin versus Methotrexate-Vincristine-Doxorubicin plus Doxorubicin-Cisplatin plus Bleomycin-Cyclophosphamide-Dactinomycin)
Medical Research Council (MRC) (UK)0 个研究点目标入组 400 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged <40 years
- •2. Biopsy proven osteosarcoma
- •3. Non-metastatic, untreated osteosarcoma of the long bones of an extremity
- •4. Normal cardiac, renal, hepatic, hematologic and pulmonary function prior to entry
- •5. Patients with parosteal, periosteal, pagetoid and post irradiation sarcoma or who have an inoperable tumour are excluded
- •6. No previous chemotherapy
- •7. No previous radiotherapy to the primary tumour
- •8. No medical contraindications to treatment
排除标准
- •Not provided at time of registration.
研究者
相似试验
已完成
不适用
Randomised trial of two schedules of chemotherapy of the same dose/time intensity in untreated small cell lung cancer (SCLC) of poor prognosisung (small cell)Lung (small cell)CancerISRCTN92669260K Co-ordinating Committee for Cancer Research (UKCCCR)
进行中（未招募）
不适用
A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients - NDWomen with histologic or cytologic diagnosis of advanced breast cancer, who have received one prior chemotherapy containing anthracyclines as neo adjuvant or palliative 1st-line treatment and one prior chemotherapy containing taxanes as neo adjuvant or palliative 1st-line treatment.MedDRA version: 8.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2006-000441-19-ITELI LILLY160
进行中（未招募）
不适用
A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients.advanced breast cancerMedDRA version: 8.0Level: LLTClassification code 10006285EUCTR2006-000441-19-DEEli lilly and Company Limited144
已完成
2 期
Randomized phase II study comparing chemotherapy led by using the classification of primary tumor origin with empirical chemotherapy for patients with unknown primary cancer .JPRN-UMIN000001919Ministry of Health, Labour and Welfare scientific research Nakagawa squad120
进行中（未招募）
不适用
Randomised Study Comparing an Immuno-Chemotherapy with 6 Cycles of the Monoclonal anti-CD20 Antibody Rituximab in Combination with 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, both with or without consolidating Radiotherapy of Large Tumour Masses (≥ 7.5 cm) and/or Extranodal Involvement in Patients with Aggressive CD20+ B-Cell Lymphoma Aged 18 to 60 Years with Age-adjusted IPI=1 (all) or IPI=0 with Bulky Disease (≥ 7.5 cm) - UNFOLDEREUCTR2005-005218-19-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI1,072